These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28279194)

  • 1. CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success?
    Gerace D; Martiniello-Wilks R; Nassif NT; Lal S; Steptoe R; Simpson AM
    Stem Cell Res Ther; 2017 Mar; 8(1):62. PubMed ID: 28279194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do we really need to differentiate mesenchymal stem cells into insulin-producing cells for attenuation of the autoimmune responses in type 1 diabetes: immunoprophylactic effects of precursors to insulin-producing cells.
    Sharma A; Rani R
    Stem Cell Res Ther; 2017 Jul; 8(1):167. PubMed ID: 28701182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Induced Pluripotent Stem Cells in the Curative Treatment of Diabetes and Potential Impediments Ahead.
    Dadheech N; James Shapiro AM
    Adv Exp Med Biol; 2019; 1144():25-35. PubMed ID: 30569414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal stem cells and differentiated insulin producing cells are new horizons for pancreatic regeneration in type I diabetes mellitus.
    Domouky AM; Hegab AS; Al-Shahat A; Raafat N
    Int J Biochem Cell Biol; 2017 Jun; 87():77-85. PubMed ID: 28385600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stem cells in the treatment of type 1 diabetes mellitus.
    Katuchova J; Harvanova D; Spakova T; Kalanin R; Farkas D; Durny P; Rosocha J; Radonak J; Petrovic D; Siniscalco D; Qi M; Novak M; Kruzliak P
    Endocr Pathol; 2015 May; 26(2):95-103. PubMed ID: 25762503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multipotent mesenchymal stromal cells from patients with newly diagnosed type 1 diabetes mellitus exhibit preserved in vitro and in vivo immunomodulatory properties.
    Yaochite JN; de Lima KW; Caliari-Oliveira C; Palma PV; Couri CE; Simões BP; Covas DT; Voltarelli JC; Oliveira MC; Donadi EA; Malmegrim KC
    Stem Cell Res Ther; 2016 Jan; 7():14. PubMed ID: 26781648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stem cell-based therapy for the treatment of type 1 diabetes mellitus.
    Mabed M; Shahin M
    Curr Stem Cell Res Ther; 2012 May; 7(3):179-90. PubMed ID: 22023626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in therapeutic CRISPR/Cas9 genome editing.
    Savić N; Schwank G
    Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a "Trojan Horse".
    Karpov DS; Sosnovtseva AO; Pylina SV; Bastrich AN; Petrova DA; Kovalev MA; Shuvalova AI; Eremkina AK; Mokrysheva NG
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stem cell-based therapy for type 1 diabetes.
    Wu H; Mahato RI
    Discov Med; 2014 Mar; 17(93):139-43. PubMed ID: 24641956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes.
    Vija L; Farge D; Gautier JF; Vexiau P; Dumitrache C; Bourgarit A; Verrecchia F; Larghero J
    Diabetes Metab; 2009 Apr; 35(2):85-93. PubMed ID: 19230736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
    Zhang Y; Sastre D; Wang F
    Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation of differentiated umbilical cord mesenchymal cells under kidney capsule for control of type I diabetes in rat.
    Moshrefi M; Yari N; Nabipour F; Bazrafshani MR; Nematollahi-mahani SN
    Tissue Cell; 2015 Aug; 47(4):395-405. PubMed ID: 26025422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New tools for experimental diabetes research: Cellular reprogramming and genome editing.
    Otonkoski T
    Ups J Med Sci; 2016 May; 121(2):146-50. PubMed ID: 27007444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplantation of mesenchymal stem cells improves type 1 diabetes mellitus.
    Li L; Li F; Gao F; Yang Y; Liu Y; Guo P; Li Y
    Cell Tissue Res; 2016 May; 364(2):345-55. PubMed ID: 26650464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Mesenchymal Stromal Cells in Islet Transplantation.
    Arzouni AA; Vargas-Seymour A; Nardi N; J F King A; Jones PM
    Stem Cells Transl Med; 2018 Aug; 7(8):559-563. PubMed ID: 29749717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro Generated Mesenchymal Stem Cells: Suitable Tools to Target Insulin Dependent Diabetes Mellitus?
    Dave SD; Patel CN; Patel JV; Thakkar UG
    Curr Stem Cell Res Ther; 2017; 12(4):288-299. PubMed ID: 27903221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing the Therapeutic Potential of Mesenchymal Stem Cells with the CRISPR-Cas System.
    Filho DM; de Carvalho Ribeiro P; Oliveira LF; Dos Santos ALRT; Parreira RC; Pinto MCX; Resende RR
    Stem Cell Rev Rep; 2019 Aug; 15(4):463-473. PubMed ID: 31147819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing Mesenchymal Stem Cell Therapy with CRISPR/Cas9 for Clinical Trial Studies.
    Golchin A; Shams F; Karami F
    Adv Exp Med Biol; 2020; 1247():89-100. PubMed ID: 31974923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of Genome-Editing Technologies for Type 1 Diabetes.
    El Nahas R; Al-Aghbar MA; Herrero L; van Panhuys N; Espino-Guarch M
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.